Model | Variablea | R2 | Δ R2 | Δ F | β | p | Variableb | R2 | Δ R2 | Δ F | β | p | Variablec | R2 | Δ R2 | Δ F | β | p |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 |  | .27 | – | 53.83 |  | .000 |  | .21 | – | 33.61 |  | .000 |  | .23 | – | 29.46 |  | .000 |
 | SSE intentions |  |  |  | .52 | .000 | SSE intentions |  |  |  | .46 | .000 | SSE intentions |  |  |  | .48 | .000 |
2 | Â | .31 | .04 | 7.68 | Â | .006 | Â | .25 | .04 | 6.72 | Â | .011 | Â | .32 | .09 | 13.18 | Â | .000 |
 | SSE intentions |  |  |  | .54 | .000 | SSE intentions |  |  |  | .35 | .000 | SSE Intentions |  |  |  | .44 | .000 |
 | Sex (male) |  |  |  | .19 | .006 | Self-efficacy |  |  |  | .23 | .011 | Melanoma stage |  |  |  | .30 | .000 |
3 | Â | .34 | .03 | 6.79 | Â | .010 | Â | .27 | .03 | 4.35 | Â | .039 | Â | .42 | .09 | 15.55 | Â | .000 |
 | SSE intentions |  |  |  | .45 | .000 | SSE intentions |  |  |  | .34 | .000 | SSE Intentions |  |  |  | .43 | .000 |
 | Sex (male) |  |  |  | .19 | .008 | SSE self-efficacy |  |  |  | .19 | .028 | Melanoma stage |  |  |  | .32 | .000 |
 | SSE self-efficacy |  |  |  | .20 | .010 | Melanoma stage |  |  |  | .16 | .039 | Education (in years) |  |  |  | −.31 | .000 |
4 | Â | .36 | .36 | .02 | Â | .045 | Â | .30 | .03 | 4.22 | Â | .042 | Â | .44 | .03 | 4.60 | Â | .035 |
 | SSE intentions |  |  |  | .43 | .000 | SSE intentions |  |  |  | .32 | .000 | SSE Intentions |  |  |  | .32 | .001 |
 | Sex (male) |  |  |  | .17 | .014 | SSE self-efficacy |  |  |  | .20 | .020 | Melanoma stage |  |  |  | .27 | .001 |
 | SSE self-efficacy |  |  |  | .18 | .023 | Melanoma stage |  |  |  | .16 | .042 | Education (in years) |  |  |  | −.29 | .000 |
 | Melanoma stage |  |  |  | .14 | .045 | Education (in years) |  |  |  | −.16 | .042 | SSE self-efficacy |  |  |  | .20 | .000 |
5 |  | .38 | .02 | 3.93 |  | .049 | bOverall F (4, 129) = 13.18, p < .001 | cOverall F (4, 100) = 18.95, p < .001 | ||||||||||
 | SSE intentions |  |  |  | .41 | .000 |  |  |  |  |  |  |  |  |  |  |  |  |
 | Sex (male) |  |  |  | .15 | .029 |  |  |  |  |  |  |  |  |  |  |  |  |
 | SSE self-efficacy |  |  |  | .17 | .029 |  |  |  |  |  |  |  |  |  |  |  |  |
 | Melanoma stage |  |  |  | .15 | .045 |  |  |  |  |  |  |  |  |  |  |  |  |
 | FKV-2 |  |  |  | .14 | .049 |  |  |  |  |  |  |  |  |  |  |  |  |
 | aOverall F (4, 144) = 16.95, p < .001 |  |  |  |  |  |  |  |  |  |  |  |  |